 This study will evaluate the efficacy, safety, and pharmacoeconomics of treatment with subcutaneous SC epoetin beta NeoRecormon in participants with hematologic malignancies or solid tumors. The anticipated time on study treatment is 20 weeks, and the target sample size is 60 individuals. 